Next-gen intranasal vaccine takes on measles, mumps, and mul

Researchers developed an intranasal trivalent measles-mumps-SARS-CoV-2 vaccine that provides robust protection against multiple coronavirus variants. Leveraging the established measles-mumps-rubella platform, this vaccine demonstrates broad and adaptable immune responses, especially against Delta and Omicron variants.

Related Keywords

Syria , Syrian , , Ohio State University Institutional Laboratory Animal Care , Severe Acute Respiratory Syndrome Coronavirus , Measles Virus , Mumps Virus , Reverse Transcription Polymerase Chain Reaction , Ohio State University , Institutional Laboratory Animal Care , Use Committee , Enzyme Linked Immunosorbent Assay , Golden Syrian Hamsters , Coronavirus Disease Covid 19 , Measles , Lumps , Vaccine , Antibodies , Ntibody , Fell , Coronavirus , Gene , Enome , Immune Response , Immunity , Immunization , Mmunoglobulin , Mr , Micron , Pandemic , Protein , Research , Espiratory , Rubella , Cars , Ars Cov 2 , Evere Acute Respiratory , Evere Acute Respiratory Syndrome , Yndrome , T Cell , Virus ,